Synairgen plc Grant of Options (4597T)
2023年11月15日 - 4:00PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMSNG
RNS Number : 4597T
Synairgen plc
15 November 2023
Synairgen plc
('Synairgen' or the 'Company')
Grant of Options
Southampton, UK - 15 November 2023: Synairgen plc (LSE: SNG),
the respiratory company developing SNG001, an investigational
formulation for inhalation containing the broad-spectrum antiviral
protein interferon beta, announces that on 14 November 2023 the
Board of Synairgen granted options ('Options') over 1,900,000
ordinary shares of one pence each in the capital of the Company
('Ordinary Shares') at an exercise price of one pence per Ordinary
Share. The Options represent in aggregate 0.94 per cent. of the
Company's issued share capital.
Following this grant, Synairgen has 18,940,446 options in issue,
representing 9.41 per cent. of the Company's issued share
capital.
Certain Options were issued to the recently recruited Chief
Financial Officer and Chief Medical Officer respectively, the
former a Director of the Company; the later a Persons Discharging
Managerial Responsibilities ('PDMR'):
Percentage
Options holding of
issued 14 Total Ordinary Total fully diluted
Nov 2023 options shares interest share capital
Directors
---------- --------- --------- ---------- ---------------
Joseph Colliver 750,000 750,000 - 750,000 0.34%
---------- --------- --------- ---------- ---------------
PDMRs
---------- --------- --------- ---------- ---------------
Marcin Mankowski 750,000 750,000 - 750,000 0.34%
---------- --------- --------- ---------- ---------------
The Options are issued under the Company's Long Term Incentive
Plan and are exercisable up to 13 November 2033, subject to the
achievement of appropriate performance criteria which match the
criteria for the 2022 award as set out on page 23 of the 2022
annual report.
The information contained within this announcement is deemed to
constitute inside information as stipulated under the retained EU
law version of the Market Abuse Regulation (EU) No. 596/2014 (the
"UK MAR") which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018.
For further enquiries, please contact:
Synairgen plc
Media@synairgen.com
Tel: + 44 (0) 23 8051 2800
Cavendish Capital Markets Limited (NOMAD and Joint Broker)
Geoff Nash, Charlie Beeson (Corporate Finance)
Sunila de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Deutsche Numis (Joint Broker)
Freddie Barnfield, Duncan Monteith, Euan Brown
Tel: + 44 (0) 20 7260 1000
ICR Consilium (Financial Media and Investor Relations)
Mary-Jane Elliott, Namrata Taak, Lucy Featherstone
cscsynairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery and the development of SNG001 (inhaled interferon beta)
as potentially the first host-targeted, broad-spectrum antiviral
treatment delivered directly into the lungs for severe viral lung
infections.
Millions of people globally are hospitalised every year due to
viral lung infections and there are currently no approved antiviral
therapies for the majority of these patients. Synairgen is
developing SNG001 to address this need.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Joseph Colliver
2. Reason for notification
a) Position / status Chief Financial Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 750,000 Options awarded
Exercise price of one pence
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 14 November 2023
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Dr Marcin Mankowski
2. Reason for notification
a) Position / status Chief Medical Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 750,000 Options awarded
Exercise price of one pence
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 14 November 2023
f) Place of the transaction Outside a trading venue
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEAEFLFEADFAA
(END) Dow Jones Newswires
November 15, 2023 02:00 ET (07:00 GMT)
Synairgen (LSE:SNG)
過去 株価チャート
から 10 2024 まで 11 2024
Synairgen (LSE:SNG)
過去 株価チャート
から 11 2023 まで 11 2024
